New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020.
Two posters that highlight findings from a Horizon sponsored survey of endocrinologists will also be presented. The first poster illustrates endocrinologists’ perceptions of the impact of TED on patient quality of life (QoL). The second poster discusses the treatment strategies used by endocrinologists to help manage this serious, progressive and vision-threatening disease in patients with TED.
Presentation Details:
Oral Presentation: Efficacy of Teprotumumab, an Insulin-like Growth Factor-1 Receptor Antagonist Antibody, in Patients with Active Thyroid Eye Disease: Pooled Results from Two Placebo-Controlled Trials
- Speaker: George J. Kahaly, M.D., Ph.D., professor of medicine and endocrinology and metabolism, Johannes Gutenberg University Medical Center
- Session: Highlighted Oral Abstracts Session
- Date: Thursday, Oct. 31, 2019
- Time: 8:50-10:05 a.m. Central Time
Poster: Impact of Thyroid Eye Disease on Patient Quality of Life as Perceived by US Endocrinologists
- Study Author: Anu Sharma, University of Utah School of Medicine
- Date: Thursday, Oct. 31, 2019
Poster: Trends in thyroid eye disease treatment among US endocrinologists
- Study Author: Anu Sharma, University of Utah School of Medicine
- Date: Friday, Nov. 1, 2019
Loading ...